QQQ   423.56 (-0.54%)
AAPL   166.76 (-0.74%)
MSFT   406.11 (-1.39%)
META   504.49 (+2.09%)
GOOGL   156.47 (+0.64%)
AMZN   179.02 (-1.25%)
TSLA   149.66 (-3.72%)
NVDA   844.97 (+0.55%)
AMD   153.75 (-0.18%)
NIO   4.02 (+2.81%)
BABA   68.99 (+0.25%)
T   16.22 (+0.62%)
F   12.02 (-0.17%)
MU   112.69 (-3.13%)
GE   154.24 (-0.92%)
CGC   7.98 (+22.96%)
DIS   112.94 (+0.00%)
AMC   2.89 (-3.02%)
PFE   25.29 (-0.51%)
PYPL   62.09 (-1.85%)
XOM   118.39 (-0.20%)
QQQ   423.56 (-0.54%)
AAPL   166.76 (-0.74%)
MSFT   406.11 (-1.39%)
META   504.49 (+2.09%)
GOOGL   156.47 (+0.64%)
AMZN   179.02 (-1.25%)
TSLA   149.66 (-3.72%)
NVDA   844.97 (+0.55%)
AMD   153.75 (-0.18%)
NIO   4.02 (+2.81%)
BABA   68.99 (+0.25%)
T   16.22 (+0.62%)
F   12.02 (-0.17%)
MU   112.69 (-3.13%)
GE   154.24 (-0.92%)
CGC   7.98 (+22.96%)
DIS   112.94 (+0.00%)
AMC   2.89 (-3.02%)
PFE   25.29 (-0.51%)
PYPL   62.09 (-1.85%)
XOM   118.39 (-0.20%)
QQQ   423.56 (-0.54%)
AAPL   166.76 (-0.74%)
MSFT   406.11 (-1.39%)
META   504.49 (+2.09%)
GOOGL   156.47 (+0.64%)
AMZN   179.02 (-1.25%)
TSLA   149.66 (-3.72%)
NVDA   844.97 (+0.55%)
AMD   153.75 (-0.18%)
NIO   4.02 (+2.81%)
BABA   68.99 (+0.25%)
T   16.22 (+0.62%)
F   12.02 (-0.17%)
MU   112.69 (-3.13%)
GE   154.24 (-0.92%)
CGC   7.98 (+22.96%)
DIS   112.94 (+0.00%)
AMC   2.89 (-3.02%)
PFE   25.29 (-0.51%)
PYPL   62.09 (-1.85%)
XOM   118.39 (-0.20%)
QQQ   423.56 (-0.54%)
AAPL   166.76 (-0.74%)
MSFT   406.11 (-1.39%)
META   504.49 (+2.09%)
GOOGL   156.47 (+0.64%)
AMZN   179.02 (-1.25%)
TSLA   149.66 (-3.72%)
NVDA   844.97 (+0.55%)
AMD   153.75 (-0.18%)
NIO   4.02 (+2.81%)
BABA   68.99 (+0.25%)
T   16.22 (+0.62%)
F   12.02 (-0.17%)
MU   112.69 (-3.13%)
GE   154.24 (-0.92%)
CGC   7.98 (+22.96%)
DIS   112.94 (+0.00%)
AMC   2.89 (-3.02%)
PFE   25.29 (-0.51%)
PYPL   62.09 (-1.85%)
XOM   118.39 (-0.20%)
Free Trial

Cardiff Oncology (CRDF) Stock Forecast & Price Target

→ Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad)
Free crdf Stock Alerts
$4.36
-0.14 (-3.11%)
(As of 01:58 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Cardiff Oncology Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 2 Analyst Ratings

Analysts' Consensus Price Target

$10.50
140.83% Upside
High Forecast$14.00
Average Forecast$10.50
Low Forecast$7.00
TypeCurrent Forecast
4/19/23 to 4/18/24		1 Month Ago
3/20/23 to 3/19/24		3 Months Ago
1/19/23 to 1/19/24		1 Year Ago
4/19/22 to 4/19/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$10.50$10.50$13.00$8.33
Predicted Upside140.83% Upside244.15% Upside728.03% Upside259.71% Upside
Get Cardiff Oncology Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.

CRDF Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CRDF Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cardiff Oncology Stock vs. The Competition

TypeCardiff OncologyMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside133.33% Upside934.49% Upside12.27% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/6/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$12.00 ➝ $14.00+283.56%
3/1/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$5.00 ➝ $7.00+185.48%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:18 PM ET.

CRDF Price Target - Frequently Asked Questions

What is Cardiff Oncology's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Cardiff Oncology stock is Buy based on the current 2 buy ratings for CRDF. The average twelve-month price prediction for Cardiff Oncology is $10.50 with a high price target of $14.00 and a low price target of $7.00. Learn more on CRDF's analyst rating history.

Do Wall Street analysts like Cardiff Oncology more than its competitors?

Analysts like Cardiff Oncology more than other Medical companies. The consensus rating for Cardiff Oncology is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how CRDF compares to other companies.

Does Cardiff Oncology's stock price have much upside?

According to analysts, Cardiff Oncology's stock has a predicted upside of 244.15% based on their 12-month stock forecasts.

What analysts cover Cardiff Oncology?

Cardiff Oncology has been rated by HC Wainwright, and Piper Sandler in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:CRDF) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
Emergency: Biden's $20 Trillion Mistake Could Cost YOU!
GoldenCrest Metals
Biden’s $374B Giveaway Into This Sector
DTI
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
He Is Giving Away Bitcoin
Crypto Swap Profits